Hormonal
Oral semaglutide (50 mg once daily) is effective for weight loss in non-diabetic obese/overweight adults, though generally less effective than the subcutaneous 2.4 mg formulation.
If you prefer not to use injections, oral semaglutide (50 mg daily) is a viable option for weight loss in non-diabetic adults with obesity. It produces significant weight loss (average 15%), though it requires daily adherence. It is generally considered less effective than the weekly injectable form, so discuss with your provider which form best fits your lifestyle and medical needs.
This trial demonstrated the greatest magnitude of weight loss achieved by an oral anti-obesity agent to date. Over the course of 68 weeks, once-daily oral 50 mg semaglutide resulted in an estimated mean body weight change of 15.1%, compared to -2.4% via matching placebo [14].
Why this rating
Based on one RCT (OASIS 1) included in the review.
Source
Efficacy of Different Doses and Forms of the GLP-1 Receptor Agonist Semaglutide in Weight Reduction Among Non-diabetic Obese or Overweight Populations
Nazeefa Fatima et al. · Cureus · 2024
DOI 10.7759/cureus.68786
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →